Symproic (naldemedine) — Medical Mutual

Initial criteria

• Patient is age ≥ 18 years
• Patient has a documented diagnosis of chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do NOT require frequent (e.g., weekly) dosage escalations

Reauthorization criteria

• Response to therapy is required for continuation of therapy

Approval duration

365 days